Skip Navigation

Publicaciones covid-9

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19

Nicole Doria‑Rose, Mehul S. Suthar, Mat Makowski, Sarah O’Connell, Adrian B. McDermott, Britta Flach, .
Julie E. Ledgerwood, John R. Mascola, Barney S. Graham, Bob C. Lin, Sijy O’Dell, Stephen D. Schmidt,
Alicia T. Widge, Venkata‑Viswanadh Edara, Evan J. Anderson, Lilin Lai, Katharine Floyd, Nadine G. Rouphael, Veronika Zarnitsyna, Paul C. Roberts, Mamodikoe Makhene, Wendy Buchanan, Catherine J. Luke,
John H. Beigel, Lisa A. Jackson, Kathleen M. Neuzil, Hamilton Bennett, Brett Leav, Jim Albert, Pratap Kunwar,
?  Evaluación: (not yet rated)
Resumen

Interim results from a phase 3 trial of the Moderna mRNA-1273 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine indicated 94% efficacy in preventing coronavirus disease 2019 (Covid-19).1 The durability of protection is currently unknown. We describe mRNA1273-elicited binding and neutralizing antibodies in 33 healthy adult participants in an ongoing phase 1 trial,2-4 stratified according to age, at 180 days after the second dose of 100 μg (day 209).

Procedencia del autor
Texto completo
Tipo de documento
Especialidad(es)
Publicado en el sitio 2021-04-22 13:13:03

Comentarios

(aún no hay comentarios disponibles para este recurso)